Development of a Method to Measure mRNA Levels From the Skin of Patients With Psoriasis and Patients With Atopic Dermatitis Using Tape Strippings
Innovaderm Research Inc.'s study focuses on developing a non-invasive method to measure mRNA levels in skin samples, which could enhance diagnostic capabilities and therapeutic monitoring for psoriasis and atopic dermatitis. The potential commercialization of this method could position Innovaderm favorably in the dermatology market, particularly as non-invasive diagnostic tools gain traction. The study's completion may attract interest from pharmaceutical companies seeking to integrate biomarker assessments into their clinical trials, thereby enhancing the value proposition of their dermatological products. Competitive implications include the need to monitor similar technologies and methodologies being developed by other entities in the dermatology space.
Indication: Healthy
Modality: RNA therapy
Target: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis
Sponsor: Innovaderm Research Inc.
Source URL: ClinicalTrials.gov
Source updated: Sep 04, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Atopic Dermatitis Eczema
View original source fields
Condition raw: Healthy, Atopic Dermatitis Eczema, Psoriasis
Condition normalized: Healthy, Atopic Dermatitis Eczema, Psoriasis
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis
Target normalized: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis